---
title: "AbbVie’s lutikizumab meets Phase 3 endpoint in hidradenitis suppurativa but falls short of market"
id: "stat-news-1-stat-abbvie-skin-disorder-drug-succeeds-in-late-stage-trial-but-results-miss"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-abbvie-skin-disorder-drug-succeeds-in-late-stage-trial-but-results-miss"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/?utm_campaign=rss"
published_at: "2026-10-22T18:22:27.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# AbbVie’s lutikizumab meets Phase 3 endpoint in hidradenitis suppurativa but falls short of market
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-abbvie-skin-disorder-drug-succeeds-in-late-stage-trial-but-results-miss
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/?utm_campaign=rss)
- **Published At:** 2026-10-22T18:22:27.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- AbbVie reported Phase 3 Intrepid results for **lutikizumab** in **hidradenitis suppurativa**: the trial enrolled about 1,400 patients with moderate-to-severe disease. - The study’s primary endpoint was a ≥75% reduction in inflamed nodules and abscesses at 16 weeks; 31.4% of the lutikizumab arm and 23.4% of placebo met that threshold. - Investigators reported that the trial also met eight secondary endpoints, among them measures of skin pain and frequency of flares; the source did not list each secondary outcome in detail. - Safety signals were similar between arms; the company said adverse event rates were nearly identical for placebo and treatment groups. - Market reaction and expert commentary, as reported, indicated the results fell short of Wall Street and clinician expectations and cast doubt on lutikizumab’s ability to displace UCB’s **Bimzelx**. - The source did not report statistical details (p-values), subgroup analyses, dosing specifics beyond weekly injections, demographic breakdowns, or planned regulatory timelines. - The trial name was Intrepid; the source did not provide longer-term follow-up results beyond the 16-week primary analysis. - Observers cited the modest absolute difference between arms as the core commercial concern; additional commercial or regulatory context was not provided in the source.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/?utm_campaign=rss) [ethics](https://www.statnews.com/topic/ethics/) [diagnostics](https://www.statnews.com/topic/diagnostics/) [Medical devices](https://www.statnews.com/topic/medical-devices/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [Midterms 2026](https://www.statnews.com/midterms-2026-health-care-policy-issues/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) My Account * [Settings](https://www.statnews.com/my-account/) * [Saved Stories](https://www.statnews.com/my-account/saved/) * [Billing History](https://www.statnews.com/my-account/billing/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations ## Findings dim hopes lutikizumab can compete with UCB’s Bimzelx * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * [Save this story for later](https://www.statnews.com/my-account/saved/) * [Share this article](https://www.statnews.com/2026/10/22/abbvie-lutikizumab-hidradenitis-suppurativa-drug-phase-3-results/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/10/AdobeStock_514511258-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) By [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) Oct. 22, 2026 West Coast Biotech & Life Sciences Reporter ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) 1. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") 2. [](https://x.com/JonathanWosen "X") jonathan.wosen@statnews.com Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. AbbVie reported on Thursday that an experimental therapy for hidradenitis suppurativa, a chronic skin condition, succeeded in a late-stage trial but missed market expectations, leaving experts doubtful the drug can compete with the current standard of care. In the Phase 3 Intrepid trial, which enrolled 1,400 patients with moderate-to-severe hidradenitis suppurativa, 31.4% of participants given weekly injections of AbbVie’s therapy, lutikizumab, reported a 75% or greater reduction in the number of inflamed bumps and abscesses across their skin, compared to 23.4% of those in the placebo group after 16 weeks. This measure was the study’s primary endpoint. Advertisement The company also reported that the drug met eight secondary endpoints, including improvements in skin pain and flares. Lutikizumab was generally safe and well tolerated, with adverse event rates that were nearly identical between the placebo and treatment groups. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [drug development](https://www.statnews.com/topic/drug-development/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) 1. [](https://x.com/JonathanWosen "X") 2. 3. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") West Coast Biotech & Life Sciences Reporter 1. [](https://x.com/JonathanWosen "X") 2. 3. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/The-Readout-Logo-Black-640x99.png) ### Newsletter Your morning rundown of the science, politics, and money driving biotech today Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/10/https___cdn.sanity.io_images_xq1bjtf4_production_964fa47326a827f12bf336e880b2fdc4665711e6-5973x4480-1-80x80.jpg) [I was a Theranos whistleblower. In ‘You Can See Everything,’ Elizabeth Holmes is still lying](https://www.statnews.com/2026/10/19/elizabeth-holmes-theranos-whistleblower-tyler-shultz-insider-review/) 2. ![](https://www.statnews.com/wp-content/uploads/2024/03/Adams-Biotech-Scorecard-Featured-Image-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [What to expect from the Moderna-Merck cancer vaccine data reveal](https://www.statnews.com/2026/10/22/esmo-2026-what-to-know-ahead-of-moderna-merck-cancer-vaccine-data-reveal/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Mark Cuban wants to crack open the market for rare disease treatments](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-491436280-80x80.jpg) [Why I wish you didn’t want to see Nathan Fielder’s Elizabeth Holmes documentary](https://www.statnews.com/2026/10/20/elizabeth-holmes-superpower-authenticity-vs-truth-matt-herper-take/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/10/Andrea-Carol-Miranda-in-Medford-1990-80x80.jpg) [The inherited disease my family called ‘it’ had a name, which changed everything](https://www.statnews.com/2026/10/22/rare-disease-family-name-fenib-personal-essay/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/TevaPF_Wordpress_CalendarImage-80x80.jpg) The Next Era of Biosimilars: Rewriting the Playbook Virtual Oct 19 ](https://www.statnews.com/event/next-era-of-biosimilars-rewriting-the-playbook/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/ESMORecap_Wordpress_CalendarImage-80x80.jpg) ESMO 2026: The STAT Recap Virtual Oct 29 ](https://www.statnews.com/event/esmo-2026-the-stat-recap/) [ ![](https://www.statnews.com/wp-content/uploads/2026/09/2026ASH_Wordpress_CalendarImage-80x80.jpg) STAT@ASH: Medicine’s Bleeding Edge New Orleans, LA Dec 13 ](https://www.statnews.com/event/stat-at-ash-meeting-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2025/07/GettyImages-2208174977-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In DOGE’s aftermath, federal health workers bristle at new performance reviews](https://www.statnews.com/2026/10/16/federal-performance-reviews-health-agency-employees-wary-after-doge/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/10/unnamed-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [On Wall Street, there’s trouble stirring for biotech](https://www.statnews.com/2026/10/15/wall-street-biotech-trouble-stirring/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/10/4LK3WINEDMMIR2JEHVX56ICPOY-80x80.avif) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Jury rules in favor of ousted Cambridge scientist David Sabatini, with $6 million in damages to be awarded](https://www.statnews.com/2026/10/16/david-sabatini-wins-sexual-misconduct-lawsuit-metoo/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/10/GettyImages-2263715743-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Mark Cuban wants to crack open the market for rare disease treatments](https://www.statnews.com/2026/10/21/mark-cuban-cost-plus-drugs-rare-disease-medicines/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/STAT26_NoSurprisesAct_Fin-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [How the No Surprises Act’s nonprofit arbitrators are operating like ‘mini gods’ and getting rich doing it](https://www.statnews.com/2026/10/19/no-surprises-act-billing-arbitration-profits-stat-investigation/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Breaking News Breaking News October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Detailed data confirm Moderna and Merck cancer vaccine met key endpoints in melanoma trial ](https://www.statnews.com/2026/10/22/esmo-moderna-merck-cancer-vaccine-intismeran-data-released/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) and [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) The Readout The Readout October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Will the Treasury restrict U.S. investment in the Chinese biotech sector? ](https://www.statnews.com/2026/10/22/biotech-news-treasury-restrictions-for-us-investment-in-chinese-biotech/) By [Meghana Keshavan](https://www.statnews.com/staff/meghana-keshavan/) and [John Wilkerson](https://www.statnews.com/staff/john-wilkerson/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What to expect from the Moderna-Merck cancer vaccine data reveal ](https://www.statnews.com/2026/10/22/esmo-2026-what-to-know-ahead-of-moderna-merck-cancer-vaccine-data-reveal/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Tech Newsletter Health Tech Newsletter October 22, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA finalizes its guidance on apps related to drugs, pharma rejoices ](https://www.statnews.com/2026/10/22/fda-pdurs-guidance-dtx-telehealth-glp1-addiction-health-tech/) By [Mario Aguilar](https://www.statnews.com/staff/mario-aguilar/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) AI Prognosis AI Prognosis October 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: What’s the deal with Isomorphic Labs? ](https://www.statnews.com/2026/10/21/whats-the-deal-with-isomorphic-labs-ai-prognosis/) By [Brittany Trang](https://www.statnews.com/staff/brittany-trang/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: How the No Surprises Act’s nonprofit arbitrators are operating like 'mini gods' and getting rich doing it ](https://www.statnews.com/2026/10/19/no-surprises-act-billing-arbitration-profits-stat-investigation/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Does Isomorphic Labs have what it takes to revolutionize drugmaking? ](https://www.statnews.com/2026/10/19/can-isomorphic-labs-revolutionize-drugmaking/) By [Allison DeAngelis](https://www.statnews.com/staff/allison-deangelis/) 3. ### [ I was a Theranos whistleblower. In ‘
## Related Clinical Research

- [What to read before you see the new Elizabeth Holmes documentary](https://medichelpline.com/clinical-feed/stat-news-4-what-to-read-before-you-go-see-that-new-documentary-on-elizabeth-holmes.md)
- [Jury Hears Competing Accounts in David Sabatini Civil Trial Over Lab Conduct](https://medichelpline.com/clinical-feed/stat-news-0-stat-coerced-sex-or-a-jealous-ex-jury-weighs-dueling-accounts-of-star-scientist.md)
- [Statin Use Linked to Reduced Glaucoma Risk in Recent Study](https://medichelpline.com/clinical-feed/medical-news-today-0-statins-may-help-lower-glaucoma-risk-study-finds.md)
- [Semaglutide plus menopause hormone therapy linked to greater weight loss in midlife women](https://medichelpline.com/clinical-feed/medical-news-today-0-ozempic-plus-hormone-therapy-may-help-boost-weight-loss-at-menopause.md)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.